Ion Beam Applications SA IBA ( (GB:0GZK) ) just unveiled an announcement.
Framatome and IBA have announced a strategic partnership to develop a network of cyclotrons for the industrial-scale production of Astatine-211, a promising radioisotope for targeted alpha therapies in oncology. This collaboration, which includes establishing a pilot production facility in France, aims to meet the growing demand for Astatine-211 and enhance cancer treatment capabilities in Europe and the United States.
More about Ion Beam Applications SA IBA
IBA (Ion Beam Applications SA) is a leader in particle accelerator technologies, primarily providing equipment and services in proton therapy, a cutting-edge form of radiotherapy. It is also involved in industrial sterilization and radiopharmaceuticals. Framatome is a prominent company in the nuclear energy sector, offering innovative solutions and technologies. Framatome Healthcare focuses on developing healthcare products and services, especially related to radioisotopes used for diagnostic imaging and cancer treatments.
YTD Price Performance: -2.25%
Average Trading Volume: 1,237
Technical Sentiment Consensus Rating: Buy
Current Market Cap: €390.3M
Learn more about 0GZK stock on TipRanks’ Stock Analysis page.